Epidemiology and Genomics Research Funding Opportunities

The Epidemiology and Genomics Research Program (EGRP) provides funding support for research in human populations to understand the causes of cancer and related outcomes. EGRP is the largest funder of cancer epidemiology grants nationally and worldwide. In addition to supporting investigator-initiated research grants, EGRP sponsors or co-sponsors a variety of targeted funding opportunity announcements (FOAs), and also is inviting participation in a prize competition. Here we provide a listing of funding opportunities that are currently accepting applications. Please visit this page regularly as new funding opportunities are added upon approval by NCI.


FOAs with EGRP Staff as Scientific Contacts

FOAs Sponsored/Co-Sponsored
by EGRP
Announcement Number
(Grant Mechanism)
Submission Dates Expiration Date
Time-Sensitive Obesity Policy and Program Evaluation
Summary Details
PAR-18-854 (R01 - Clinical Trial Not Allowed)

Oct. 10, Nov. 13, Dec. 11, 2018
Jan. 10, Feb. 11, Mar. 11, Apr. 11, May 10, June 10, July 11, Aug. 9, Sept. 12, Oct. 11, Nov. 13, Dec. 10, 2019
Jan. 10, Feb. 10, Mar. 10, Apr. 7, May 11, June 10, July 10, Aug. 11, Sept. 10, Oct. 14, Nov. 10, Dec. 11, 2020
Jan. 11, Feb. 10, Mar. 10, Apr. 9, May 10, June 11, July 9, Aug. 10, Sept. 10, 2021

Sept. 11, 2021

Summary:
This FOA establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. For more information: PAR-18-854 (R01).

Contact: Jill Reedy, Ph.D., M.P.H., R.D., Program Director, Risk Factor Assessment Branch, e-mail: reedyj@mail.nih.gov

Diet and Physical Activity Assessment Methodology
Summary Details
PA-18-856 (R01 - Clinical Trial Not Allowed)
PAR-18-857 (R21 - Clinical Trial Not Allowed)

Standard dates apply.

Sept. 8, 2021

Summary:
These Funding Opportunity Announcements (FOAs) encourage innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications may include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors. For more information: PA-18-856 (R01) and PAR-18-857 (R21).

For diet assessment questions: Amy Subar, Ph.D., Program Director, Risk Factor Assessment Branch, e-mail: subara@mail.nih.gov

For physical activity assessment questions: Richard Troiano, Ph.D., Program Director, Risk Factor Assessment Branch, e-mail: troianor@mail.nih.gov

Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression Announcement Numbers
Summary Details
PA-18-738 (R01 - Clinical Trial Optional)
PA-18-739 (R21 - Clinical Trial Optional)
Standard dates apply May 8, 2021

Summary:
The overall purpose of this funding opportunity announcement (FOA) is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as relate to health and disease. This FOA will accept basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science. For more information: PA-18-738 (R01), PA-18-739 (R21).

Contact: Tram Lam, Ph.D., M.P.H., Program Director, Environmental Epidemiology Branch; e-mail: lamt@nih.gov

Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility
Summary Details
PA-18-677 (R01 - Clinical Trial Not Allowed)
PA-18-678 (R21 - Clinical Trial Not Allowed)
Standard dates apply May 8, 2021

Summary:
The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States. This FOA only accepts applications that do not support clinical trials. See NIH definition of a clinical trial. For more information: PA-18-677 (R01), PA-18-678 (R21).

Contact: Tram Lam, Ph.D., M.P.H., Program Director, Environmental Epidemiology Branch; e-mail: lamt@nih.gov

Modular R01s in Cancer Control and Population Sciences
Summary Details
PAR-18-869 (R01 - Clinical Trial Optional) Nov. 7, 2018
Mar. 6, Nov. 7, 2019
Mar. 6, Nov. 6, 2020
Mar. 8, 2021
Mar. 9, 2021

Summary:
This funding opportunity announcement (FOA) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science. For more information: PAR-18-869 (R01).

Contact: Mr. Scott Rogers, M.P.H., Public Health Advisor, Office of the Associate Director, e-mail: rogerssc@mail.nih.gov

Mechanisms of Disparities in Etiology and Outcomes of Lung Cancer in the U.S.: The Role of Risk and Protective Factors
Summary Details
PAR-19-018 (R01 - Clinical Trial Not Allowed)
PAR-19-019 (R21 - Clinical Trial Not Allowed)
Mar. 4, 2019
Mar. 4, 2020
Mar. 4, 2021
Mar. 5, 2021

Summary:
This initiative will support multidisciplinary research to understand the underlying causal factors and mechanisms that result in lung cancer disparities in U.S. health disparity populations.The overall objective of this initiative is to support research to 1) understand the complex etiological factors (social, cultural, environmental, behavioral or biological) contributing to lung cancer disparities and 2) how health care factors affect morbidity and mortality outcomes among lung cancer patients from health disparity populations. For more information: PAR-19-018 (R01) and PAR-19-019 (R21).

Contact: Damali Martin, Ph.D., M.P.H., Program Director, Genomic Epidemiology Branch, e-mail: martinda@mail.nih.gov

Early-life Factors and Cancer Development Later in Life
Summary Details
PA-18-531 (R03 - Clinical Trial Not Allowed)
PA-18-532 (R21 - Clinical Trial Not Allowed)
PA-18-529 (R01 - Clinical Trial Not Allowed)
Standard dates apply Jan. 8, 2021

Summary:
The purpose of this FOA is to stimulate research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life. Given that the current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand 1) the early-life factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early life can be measured and developed for use in cancer prevention strategies. Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait decades for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer prevention. For more information: PA-18-529 (R01), PA-18-532 (R21), and PA-18-531 (R03).

Contact: Somdat Mahabir, Ph.D., M.P.H., Program Director, Environmental Epidemiology Branch; e-mail: mahabir@mail.nih.gov

Assay Validation of High Quality Markers for Clinical Studies in Cancer
Summary Details
PAR-18-317 (UH2/UH3 - Clinical Trial Not Allowed)
PAR-18-310 (UH3 - Clinical Trial Not Allowed)
Feb. 14, July 10, Oct. 8, 2018
Feb. 13, July 10, Oct. 8, 2019
Feb. 13, July 10, Oct. 8, 2020
Oct. 8, 2020

Summary:
The purpose of this FOA is to support the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.This FOA may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. For more information: PAR-18-317 (UH2/UH3) and PAR-18-310 (UH3).

Contact: Rao Divi, Ph.D., Program Director, Methods and Technologies Branch, e-mail: divir@mail.nih.gov; Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Administrative Supplements to Support Cancer Disparity Collaborative Research
Summary Details
PA-18-842 (Clinical Trial Optional) Sept. 10, 2018
Sept. 10, 2019
Sept. 10, 2020
Sept. 11, 2020

Summary:
The purpose of this Funding Opportunity Announcement (FOA) is to promote new cancer disparities research among investigators who do not normally conduct it and to encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers. This FOA is intended to accelerate and strengthen multi-disciplinary cancer disparities research in wide ranging areas. Cancer disparities research includes, but is not limited to basic, translational, behavioral, observational, interventional, environmental and population research studies that address the adverse differences in cancer incidence, prevalence, mortality, survivorship, burden and/or response to treatment in racial/ethnic minorities and/or underserved population groups. Proposed collaborations should focus on achieving research objectives that by necessity rely on diverse and complementary expertise, technical capabilities, and resource sets. Importantly, the supplemental request is required to be within the scope of the parent award and should expand the original aims to include a cancer disparity component. For more information: PA-18-842.

Contact: Damali Martin, Ph.D., M.P.H., Program Director, Genomic Epidemiology Branch; e-mail: martinda@mail.nih.gov

Ethical, Legal, Social Implications of Human Genome Research
Summary Details
PA-17-444 (R01)
PA-17-446 (R21)
PA-17-445 (R03)
Standard dates apply Sept. 8, 2020

Summary:
These Funding Opportunity Announcements (FOAs) invite applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Proposed approaches for R01 applications may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.Of particular interest for R21 applications are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information. For R03 applications, projects of particular interest are those that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. The R03 mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data. For more information: PA-17-444 (R01), PA-17-446 (R21), and PA-17-445 (R03).

Contact: Charlisse Caga-anan, J.D., Program Director, Genomic Epidemiology Branch, e-mail: charlisse.caga-anan@nih.gov

HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure through Clinical Research
Summary Details
PA-17-279 (R01)
PA-17-278 (R21)
Standard dates apply May 8, 2020

Summary:
This FOA invites applications proposing clinical research to identify and better understand the unique challenges to achieve a functional cure in HIV/HBV+ co-infected hosts as well as advance the discovery and development of novel strategies to achieve HBV functional cure for HIV/HBV+ co-infected adult and pediatric populations, including children, adolescents and HIV exposed uninfected children. Although clinical trials and establishment of new cohorts will not be supported by this FOA, the leveraging of ongoing NIH- or non-NIH supported clinical trials and cohorts to collect samples and data to address areas of research interests is encouraged. For more information: PAR-17-279 (R01) and PA-17-278 (R21).

Contact: Vaurice Starks, Program Director, Environmental Epidemiology Branch, e-mail: starksv@mail.nih.gov

Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts
Summary Details
PAR-17-233 (U01) Standard dates apply May 8, 2020

Summary:
Through this FOA, NCI encourages grant applications for support of the core functions of Cancer Epidemiology Cohorts (CECs), as well as methodological research. This FOA is intended to support maintenance of existing CECs infrastructure and resource sharing with broader scientific communities. For more information: PAR-17-233 (U01) and FAQs

Contact: Joanne Elena, Ph.D., M.P.H., Program Director, Clinical and Translational Epidemiology Branch, e-mail: elenajw@mail.nih.gov

Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes
Summary Details
PA-17-239 (R01)
PA-17-243 (R21)
Standard dates apply May 8, 2020

Summary:
This FOA encourages applications that propose to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes. The goal is to address key scientific questions relevant to cancer epidemiology by supporting the analysis of existing genetic or genomic datasets, possibly in combination with environmental, outcomes, behavioral, lifestyle, and molecular profiles data. Applications to this FOA are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research. For more information: PA-17-239 (R01) and PA-17-243 (R21)

Contact: Melissa Rotunno, Ph.D., Program Director, Genomic Epidemiology Branch, e-mail: rotunnom@mail.nih.gov

Genomic Community Resources
Summary Details
PAR-17-273 (U24) Standard dates apply Jan. 26, 2020

Summary:
Awards under this FOA will support the development and distribution of genomic resources that will be valuable for the broad research community, using cost-effective approaches. Such resources include (but are not limited to) databases and informatics resources (such as human and model organism databases, ontologies, and analysis toolsets), comprehensive identification and collections of genomic features (such as functional genomic elements), and standard data types produced using central sets of samples (such as structural variants in 1000 Genomes or GTEx samples). NCI is interested in any of the above types of resources that focus on cancer. For more information: PAR-17-273 (U24).

Contact: Leah Mechanic, Ph.D., M.P.H., Program Director, Genomic Epidemiology Branch. e-mail: mechanil@mail.nih.gov

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations
Summary Details
PA-17-041 (R01)
PA-17-042 (R21)
Standard dates apply Jan. 8, 2020

Summary:
The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to understand uniquely associated factors (biological, behavioral, sociocultural, and environmental) that contribute to health disparities or health advantages among U.S. immigrant populations. For more information: PA-17-041 (R01) and PA-17-042 (R21).

Contact: Damali Martin, Ph.D., M.P.H., Program Director, Genomic Epidemiology Branch, e-mail: martinda@mail.nih.gov; and Tram Lam, Ph.D., M.P.H., Program Director, Environmental Epidemiology Branch, e-mail: lamt@mail.nih.gov

Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery
Summary Details
PA-18-004 (R01 - Clinical Trial Optional)
PA-18-014 (R21 - Clinical Trial Optional)
Standard dates apply Jan. 8, 2020

Summary:
The purpose of this FOA is to encourage exploratory/developmental research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized. Applications should focus research questions on specific cancer type; class of drugs; and/or groups subject to disparities. Research may be focused at the patient, patient-caregiver, provider, health care team, or health care delivery system level, and may include intervention studies, observational studies, or mixed-methods studies. EGRP is partnering with other Programs in the Division of Cancer Control and Population Sciences (DCCPS) to sponsor this FOA. For more information: PA-18-004 (R01) and PA-18-014 (R21).

Contact: Kelly K. Filipski, Ph.D., M.P.H., Program Director, Clinical and Translational Epidemiology Branch, e-mail: filipskikk@mail.nih.gov

Clinical and Epidemiological Research on Chronic Disease in the Caribbean
Summary Details
PAR-17-470 (R01 - Clinical Trial Not Allowed) Nov. 15, 2017
Nov. 15, 2018
Nov. 15, 2019
Nov. 16, 2019

Summary:
The purpose of this Funding Opportunity Announcement (FOA) is to support U.S.-Caribbean collaborative research to develop or extend cohort or surveillance studies on chronic disease in the Caribbean region that are aligned with existing publicly available U.S. datasets. The intent is for these cohorts or datasets to be used for ongoing comparative research to better understand the health of Caribbean immigrant populations in the U.S. For more information: PAR-17-470 (R01).

Contact: Damali Martin, Ph.D., M.P.H., Program Director, Genomic Epidemiology Branch, e-mail: martinda@mail.nih.gov

"High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers
Summary Details
PA-16-426 (R01)
PA-16-425 (R21)
Standard AIDS dates apply Sept. 8, 2019

Summary:
The purpose of this FOA is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals. This FOA encourages research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection. For more information: PA-16-426 (R01) and PA-16-425 (R21).

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov; and Vaurice Starks, Program Director, Environmental Epidemiology Branch, e-mail: starksv@mail.nih.gov

Secondary Analyses of Alcohol and Chronic Disease
Summary Details
PA-16-395 (R01)
PA-16-394 (R03)
Standard dates apply Sept. 8, 2019

Summary:
This FOA encourages use of existing datasets to examine associations between alcohol and non-communicable chronic diseases. A population of particular interest is older adults, however, other populations that are understudied may be considered, including but not limited to pregnant women, pre-and post-menopausal women, cancer survivors, and other populations defined by stage-of-life and race/ethnicity. Factors of interest that may interact with alcohol include, but are not limited to, concurrent use of prescription or illicit drugs, lifestyle factors such as smoking, diet, and physical activity, and genetics including gene-environment interactions. Alcohol may be considered in numerous ways, including, but not limited to, average volume, quantity/frequency, binge, drinking with meals, lifetime drinking, and presence of alcohol use disorders. Studies examining both the benefits and harms of drinking are of interest as well as studies of moderate and heavy drinking. Sources of data may include, but are not limited to previously conducted epidemiologic studies (cross-sectional or cohort) and clinical trials. For more information: PA-16-395 (R01) and PA-16-394 (R03).

Contact: Somdat Mahabir, Ph.D., M.P.H., Program Director, Environmental Epidemiology Branch; e-mail: mahabir@mail.nih.gov

Exploratory Grants in Cancer Epidemiology and Genomics Research
Summary Details
PA-16-175 (R21) Standard dates apply May 8, 2019

Summary:
This FOA invites applications for research on cancer epidemiology, genomics, and risk assessment. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance cancer research, such as improving epidemiologic study data collection; validating measurement of exposures in body fluids and tissues; applying epigenetic or metabolomic approaches to cancer epidemiology research; developing and applying novel strategies for discovery of risk variants for rare cancers; understanding the population genetic architecture of cancer in understudied populations; or validating methods to extract, collect, and synthesize clinical data via electronic medical records for use in observational studies of cancer patients and survivors. For more information: PA-16-175 (R21).

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov

Obesity Policy Evaluation Research
Summary Details
PA-16-165 (R01) Standard dates apply May 8, 2019

Summary:
This FOA encourages applications that propose to evaluate large scale policy or programs that are expected to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. For more information: PA-16-165 (R01).

Contact: Jill Reedy, Ph.D., M.P.H., R.D., Program Director, Risk Factor Assessment Branch, e-mail: reedyj@mail.nih.gov

Mechanisms of Disparities in Chronic Liver Diseases and Cancer
Summary Details
PAR-17-151 (R01)
PAR-17-150 (R21)
Apr. 4, 2018
Apr. 4, 2019
Apr. 5, 2019

Summary:
This FOA invites applications that include multidisciplinary research to understand the influence of multiple factors that cause liver disease/cancer health disparities and the mechanisms through which they operate. Applicants are encouraged to focus on the interplay of multiple factors between genetic, behavioral, environmental and structural factors that drives the observed racial/ethnic differences in health outcome. Studies for this initiative may include multi-disciplinary epidemiological, behavioral, or health services projects that leverage understanding of the biological factors that influence chronic liver disease and hepatocellular carcinoma (HCC). In addition, projects can involve primary and/or secondary data collection and analysis. Because the goal of this initiative is to better understand documented racial/ethnic and SES disparities in chronic liver diseases and cancer, studies whose sole purpose is to assess incidence of liver disease/cancer in specific populations or subpopulations are not targeted for support under this FOA. Projects should include a focus on one or more NIH-designated health disparity populations in the United States, which include Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, socioeconomically disadvantaged populations, sexual and gender minorities and underserved rural populations. For health disparity populations with a significant proportion of immigrants, comparison of health factors between the U.S. and country of origin, length of stay may be considered when appropriate. For more information: PAR-17-151 (R01) and PAR-17-150 (R21).

Contact: Tram Lam, Ph.D., M.P.H., Program Director, Environmental Epidemiology Branch; e-mail: lamt@nih.gov

Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes
Summary Details
RFA-CA-19-017 (U01 - Clinical Trial Required) Jan. 9, 2019 Jan. 10, 2019

Summary:
The purpose of this FOA is to increase case ascertainment and appropriate follow-up care, optimizing the delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. This FOA invites multiple Program Director/Principle Investigator (multi-PD/PI) U01 applications with the goal of improving prevention and detection. For more information: RFA-CA-19-017 (U01). A recorded webinarExternal Web Site Policy is also available describing this FOA and answering some frequently asked questions.

Contact: Nonniekaye Shelburne, M.S., C.R.N.P., A.O.C.N., Program Director, Clinical and Translational Epidemiology Branch, e-mail: nshelburne@mail.nih.gov

Improving Outcomes in Cancer Treatment-Related Cardiotoxicity
Summary Details
PA-18-003 (R01 - Clinical Trial Optional)
PA-18-013 (R21 - Clinical Trial Optional)
Standard dates apply Jan. 8, 2019

Summary:
This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiac risk prior to treatment and integrate evidence-based cancer treatment regimens with screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac specific common terminology criteria for adverse events (CTCAE). For more information: PA-18-003 (R01) and PA-18-013 (R21).

Contact: Nonniekaye Shelburne, M.S., C.R.N.P., A.O.C.N., Program Director, Clinical and Translational Epidemiology Branch; e-mail: nonniekaye.shelburne@nih.gov

Social Epigenomics Research Focused on Minority Health and Health Disparities
Summary Details
PAR-16-355 (R01)
PAR-16-356 (R21)
Nov. 15, 2017
Nov. 15, 2018
Nov. 16, 2018

Summary:
The purpose of this Funding Opportunity Announcement (FOA) is to support and accelerate human epigenomic investigations focused on identifying and characterizing the mechanisms by which social experiences at various stages in life, both positive and negative, affect gene function and thereby influence health trajectories or modify disease risk in racial/ethnic minority and health disparity populations. For more information: PAR-16-355 (R01) and PAR-16-356 (R21).

Contact: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, e-mail: vermam@mail.nih.gov


Other funding opportunities of interest not sponsored by EGRP



Stay Up to Date

Subscribe to EGRP's monthly Cancer Epidemiology E-News to receive details about recent NIH FOAs and Notices of Intent to publish an FOA, as well as relevant funding opportunities from other organizations.

Return to Top